<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059682</url>
  </required_header>
  <id_info>
    <org_study_id>NC22703</org_study_id>
    <nct_id>NCT01059682</nct_id>
  </id_info>
  <brief_title>A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease</brief_title>
  <official_title>A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multicenter, double-blind, randomized, placebo-controlled study will evaluate the effect
      of dalcetrapib 600 mg on artherosclerotic disease progression, lipid profile and biomarker
      profile and long-term safety profile of dalcetrapib in patients with coronary artery disease.
      Atherosclerotic disease progression will be measured 1. Coronary Intravascular Ultrasound
      (IVUS), Quantitative Coronary Angiography 2. Carotid B-Mode Ultrasound Intima Medial
      Thickness (IMT) and total plaque volume in subjects undergoing coronary angiography who have
      coronary artery disease (CAD). Patients will be randomized to receive dalcetrapib 600 mg
      orally once a day or placebo. The anticipated time on study treatment will be 24 months. The
      target sample size is 800-1000 patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Termination of the clinical development program by the Sponsor
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Change From Baseline to Study End in Carotid Intima-media Thickness (CIMT) Using B-mode Ultrasound</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nominal Changes From Baseline in Minimal Lumen Diameter as Assessed by Quantitative Coronary Angiography</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Lipids, Lipoproteins</measure>
    <time_frame>Throughout study, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nominal Changes in Percent Diameter Stenosis as Assessed by Quantitative Coronary Angiography</measure>
    <time_frame>Throughout Study, 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">936</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Dalcetrapib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalcetrapib</intervention_name>
    <description>Dalcetrapib 600 mg orally once daily</description>
    <arm_group_label>Dalcetrapib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo orally once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients over the age of 18 years

          -  Angiographic evidence of coronary artery disease

          -  Ultrasound evidence of carotid artery disease

          -  Treated appropriately for dyslipidemia

        Exclusion Criteria:

          -  Previous exposure to any cholesteryl ester transfer protein (CETP) inhibitor or
             CETP-vaccine within the last 3 months before study start

          -  Previous coronary artery bypass graft surgery (CABG) or probable need for CABG in the
             next 24 months

          -  Myocardial infarction in the target coronary artery for IVUS between the initial IVUS
             examination and randomization

          -  Patients who have symptomatic congestive heart failure at baseline (New York Heart
             Association class III or IV)

          -  Severe anemia

          -  Uncontrolled hypertension

          -  Poorly controlled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muskegon</city>
        <state>Michigan</state>
        <zip>49444</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oak Ridge</city>
        <state>Tennessee</state>
        <zip>37830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6Z 4N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7M 4Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5K 2L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1E 4B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fleurimont</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lachine</city>
        <state>Quebec</state>
        <zip>H8S 2E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3J 2V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Georges-de-beauce</city>
        <state>Quebec</state>
        <zip>G5Y 4T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-Charles-Borromée</city>
        <state>Quebec</state>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-jerome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-Lambert</city>
        <state>Quebec</state>
        <zip>J4P 2H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ste. Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sudbury</city>
        <state>Quebec</state>
        <zip>P3E 3Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Val D'or</city>
        <state>Quebec</state>
        <zip>J9P 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdańsk</city>
        <zip>80- 952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20- 954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>01- 141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geneve</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kreuzlingen</city>
        <zip>8280</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 29, 2010</study_first_submitted>
  <study_first_submitted_qc>January 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <results_first_submitted>July 17, 2019</results_first_submitted>
  <results_first_submitted_qc>March 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2020</results_first_posted>
  <disposition_first_submitted>July 26, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>July 26, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 28, 2016</disposition_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalcetrapib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dalcetrapib</title>
          <description>Dalcetrapib: Dalcetrapib 600 mg orally once daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Placebo orally once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="474"/>
                <participants group_id="P2" count="462"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="464"/>
                <participants group_id="P2" count="444"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dalcetrapib</title>
          <description>Dalcetrapib: Dalcetrapib 600 mg orally once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Placebo orally once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="474"/>
            <count group_id="B2" value="462"/>
            <count group_id="B3" value="936"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="8.48"/>
                    <measurement group_id="B2" value="60.4" spread="8.86"/>
                    <measurement group_id="B3" value="60.5" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="347"/>
                    <measurement group_id="B2" value="354"/>
                    <measurement group_id="B3" value="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS.</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>Dalcetrapib: Dalcetrapib 600 mg orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS.</title>
          <units>Percent Change Atheroma Volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="3.69"/>
                    <measurement group_id="O2" value="0.5" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Change From Baseline to Study End in Carotid Intima-media Thickness (CIMT) Using B-mode Ultrasound</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>Dalcetrapib: Dalcetrapib 600 mg orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change From Baseline to Study End in Carotid Intima-media Thickness (CIMT) Using B-mode Ultrasound</title>
          <units>mm/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.0588"/>
                    <measurement group_id="O2" value="0.003" spread="0.0568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nominal Changes From Baseline in Minimal Lumen Diameter as Assessed by Quantitative Coronary Angiography</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>Dalcetrapib: Dalcetrapib 600 mg orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Nominal Changes From Baseline in Minimal Lumen Diameter as Assessed by Quantitative Coronary Angiography</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.18"/>
                    <measurement group_id="O2" value="0.0" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Lipids, Lipoproteins</title>
        <time_frame>Throughout study, 24 months</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>Dalcetrapib: Dalcetrapib 600 mg orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Lipids, Lipoproteins</title>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nominal Changes in Percent Diameter Stenosis as Assessed by Quantitative Coronary Angiography</title>
        <time_frame>Throughout Study, 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dalcetrapib</title>
            <description>Dalcetrapib: Dalcetrapib 600 mg orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Nominal Changes in Percent Diameter Stenosis as Assessed by Quantitative Coronary Angiography</title>
          <units>Percent Diameter Stenosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="20.65"/>
                    <measurement group_id="O2" value="4.3" spread="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dalcetrapib</title>
          <description>Dalcetrapib: Dalcetrapib 600 mg orally once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Placebo orally once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Idiopathic Thrombocytopenia Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Prinzmetal Angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Ventricular Tachicardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Diarrhea Hemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Rectal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Device Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Medical Device Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Clostridial Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Limb Traumatic Amputaton</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Post Procedural Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Post Procedural Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram Coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Heart Rate Irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Joint Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Myositis Ossificans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Adenolymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Benign Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Brain Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Breast Cancr Male</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Diffuse Large B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Malignant Melonoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Malignant Neoplasm of Ampulla of Vater</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Small Cell Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Thyroid Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Coronary Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Sleep Apnea Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Arterial Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="255" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="199" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan Black</name_or_title>
      <organization>DalCor Pharmaceuticals</organization>
      <email>rblack@dalcorpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

